Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May;87(5):534-6.
doi: 10.1038/clpt.2010.26.

Can open-source drug R&D repower pharmaceutical innovation?

B Munos  1
Affiliations
Review

Can open-source drug R&D repower pharmaceutical innovation?

B Munos. Clin Pharmacol Ther. 2010 May.

Abstract

Open-source R&D initiatives are multiplying across biomedical research. Some of them-such as public-private partnerships-have achieved notable success in bringing new drugs to market economically, whereas others reflect the pharmaceutical industry's efforts to retool its R&D model. Is open innovation the answer to the innovation crisis? This Commentary argues that although it may likely be part of the solution, significant cultural, scientific, and regulatory barriers can prevent it from delivering on its promise.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Precompetitive consortia in biomedicine--how are we doing?
    Mittleman B, Neil G, Cutcher-Gershenfeld J. Mittleman B, et al. Nat Biotechnol. 2013 Nov;31(11):979-85. doi: 10.1038/nbt.2731. Nat Biotechnol. 2013. PMID: 24213770 No abstract available.
  • Obstacles and opportunities in Chinese pharmaceutical innovation.
    Ni J, Zhao J, Ung CO, Hu Y, Hu H, Wang Y. Ni J, et al. Global Health. 2017 Mar 24;13(1):21. doi: 10.1186/s12992-017-0244-6. Global Health. 2017. PMID: 28340579 Free PMC article.
  • Crowd sourcing a new paradigm for interactome driven drug target identification in Mycobacterium tuberculosis.
    Vashisht R, Mondal AK, Jain A, Shah A, Vishnoi P, Priyadarshini P, Bhattacharyya K, Rohira H, Bhat AG, Passi A, Mukherjee K, Choudhary KS, Kumar V, Arora A, Munusamy P, Subramanian A, Venkatachalam A, Gayathri S, Raj S, Chitra V, Verma K, Zaheer S, Balaganesh J, Gurusamy M, Razeeth M, Raja I, Thandapani M, Mevada V, Soni R, Rana S, Ramanna GM, Raghavan S, Subramanya SN, Kholia T, Patel R, Bhavnani V, Chiranjeevi L, Sengupta S, Singh PK, Atray N, Gandhi S, Avasthi TS, Nisthar S, Anurag M, Sharma P, Hasija Y, Dash D, Sharma A, Scaria V, Thomas Z; OSDD Consortium; Chandra N, Brahmachari SK, Bhardwaj A. Vashisht R, et al. PLoS One. 2012;7(7):e39808. doi: 10.1371/journal.pone.0039808. Epub 2012 Jul 11. PLoS One. 2012. PMID: 22808064 Free PMC article.
  • Promising Trends in Access to Medicines.
    Richard Gold E, Morin JF. Richard Gold E, et al. Glob Policy. 2012 May;3(2):231-237. doi: 10.1111/j.1758-5899.2011.00110.x. Epub 2012 May 22. Glob Policy. 2012. PMID: 32336993 Free PMC article.
  • The European Lead Factory: A Blueprint for Public-Private Partnerships in Early Drug Discovery.
    Karawajczyk A, Orrling KM, de Vlieger JS, Rijnders T, Tzalis D. Karawajczyk A, et al. Front Med (Lausanne). 2017 Jan 19;3:75. doi: 10.3389/fmed.2016.00075. eCollection 2016. Front Med (Lausanne). 2017. PMID: 28154815 Free PMC article. Review.
See all "Cited by" articles

MeSH terms

LinkOut - more resources